Skip to Content
E. Jason Abel, MD, FACS

Contact Dr. Abel

E-mail:
abel@urology.wisc.edu

Phone:
(608) 263-4563

Mail:
UW Medical Foundation Centennial Building
1685 Highland Ave
Madison, WI 53705-2281

E. Jason Abel, MD, FACS

Associate Professor
Department of Urology

Education

  • BS, Zoology; BA, Molecular Biology, University of Texas at Austin, 1998
  • MD, The University of Texas at Houston Medical School, 2003
  • Residency, University of Utah Division of Urology, Salt Lake City, UT, 2008
  • Fellowship, Urologic Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, 2010

Dr. Abel specializes in the surgical treatment of urologic malignancies. He has advanced training to surgically manage all types of genitourinary cancers including prostate cancer, bladder cancer, kidney cancer, testis cancer and penile cancer.

Clinical Specialties

Dr. Abel is certified by the American Board of Urology. He performs open and laparoscopic surgery including surgery using the daVinci robot. Dr Abel’s philosophy is to provide maximal quality of life to patients by using minimally invasive approaches to cancer therapy whenever appropriate. He has a special interest in the treatment of localized and locally advanced kidney cancer.

Research Interests

Dr. Abel conducts clinical, translational, and basic research in urologic oncology. Clinical and translational interests include improving patient outcomes after complex urologic surgery, improving prognostic ability for patient decision making, and multidisciplinary care of kidney cancer.

Dr. Abel serves on the board of directors for the Society of Urologic Oncology (SUO) Clinical Trials Consortium.

Funding/Grants
  • Role of NFXB/HIF2A Axis in Renal Cell Carcinoma Progression
    Funding Agency: National Institutes of Health (NIH); National Cancer Institute (NCI) Career Development Award 1K08CA178168-01
    Principal Investigator(s): E. Jason Abel, MD, FACS
    More Information

Recent Publications
  • Richards KA, Abel EJ. Surveillance following surgery for nonmetastatic renal cell carcinoma. Curr Opin Urol 2016 Sep; 26(5):432-8.
    [PubMed ID: 27467135]
    More Information
  • Bauman TM, Huang W, Lee MH, Abel EJ. Neovascularity as a Prognostic Marker in Renal Cell Carcinoma. Hum. Pathol. 2016 Jul 16.
    [PubMed ID: 27436827]
    More Information
  • Grimes MD, Blute ML, Wittmann TA, Mann MA, Zorn K, Downs TM, Shi F, Jarrard DF, Best SL, Richards KA, Nakada SY, Abel EJ. A Critical Analysis of Perioperative Outcomes in Morbidly Obese Patients Following Renal Mass Surgery. Urology 2016 Jun 20.
    [PubMed ID: 27339026]
    More Information
  • Lubner MG, Stabo N, Abel EJ, Del Rio AM, Pickhardt PJ. CT Textural Analysis of Large Primary Renal Cell Carcinomas: Pretreatment Tumor Heterogeneity Correlates With Histologic Findings and Clinical Outcomes. AJR Am J Roentgenol 2016 Jul; 207(1):96-105.
    [PubMed ID: 27145377]
    More Information
  • Blute ML, Abel EJ. The evolving role of renal mass biopsy. Ann Transl Med 2016 Feb; 4(4):83.
    [PubMed ID: 27004230, PMCID: 4779777]
    More Information
  • Abel EJ. Re: Lorenzo Marconi, Saeed Dabestani, Thomas B. Lam, et al. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. Eur Urol 2016;69:660-73: The Search for Accurate Diagnostic Rates in Renal Mass Biopsy. Eur. Urol. 2016 Jun; 69(6):e117-8.
    [PubMed ID: 26778464]
    More Information
  • Blute ML, Zorn K, Grimes M, Shi F, Downs TM, Jarrard DF, Best SL, Richards K, Nakada SY, Abel EJ. Extreme obesity does not predict poor cancer outcomes after surgery for renal cell cancer. BJU Int. 2016 Sep; 118(3):399-407.
    [PubMed ID: 26589741]
    More Information
  • Abel EJ, Margulis V, Bauman TM, Karam JA, Christensen WP, Krabbe LM, Haddad A, Golla V, Wood CG. Risk factors for recurrence after surgery in non-metastatic RCC with thrombus: a contemporary multicentre analysis. BJU Int. 2016 Jun; 117(6B):E87-94.
    [PubMed ID: 26305276]
    More Information
  • Blute ML, Drewry A, Abel EJ. Percutaneous biopsy for risk stratification of renal masses. Ther Adv Urol 2015 Oct; 7(5):265-74.
    [PubMed ID: 26425141, PMCID: 4549697]
    More Information
  • Cristescu M, Abel EJ, Wells S, Ziemlewicz TJ, Hedican SP, Lubner MG, Hinshaw JL, Brace CL, Lee FT. Percutaneous Microwave Ablation of Renal Angiomyolipomas. Cardiovasc Intervent Radiol 2016 Mar; 39(3):433-40.
    [PubMed ID: 26390876]
    More Information


webmaster@surgery.wisc.edu Copyright © 2016 The Board of Regents of the University of Wisconsin System